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AbstrAct
Trpv5 plays an important role in calcium (Ca2+) homeostasis, among others by 
mediating renal calcium reabsorption. Accordingly, Trpv5 deficiency strongly stresses 
Ca2+ homeostasis in order to maintain stable serum Ca2+. We addressed the impact 
of lifelong challenge of calcium homeostasis on the bone phenotype of these mice.
Aging significantly increased serum 1,25(OH)2D3 and PTH levels in both genotypes 
but they were more elevated in Trpv5-/- mice, whereas serum Ca2+ was not affected 
by age or genotype. Age-related changes in trabecular and cortical bone mass were 
accelerated in Trpv5-/- mice, including reduced trabecular and cortical bone thickness 
as well as reduced bone mineralization. No effect of Trpv5 deficiency on bone strength 
was observed. In 78-week-old mice no differences were observed between the 
genotypes regarding urinary deoxypyridinoline, osteoclast number, differentiation 
and activity as well as osteoclast precursor numbers, as assessed by flow cytometry.
In conclusion, life-long challenge of Ca2+ homeostasis present in Trpv5-/- mice 
causes accelerated bone aging and a low cortical and trabecular bone mass phenotype. 
The phenotype of the Trpv5-/- mice suggests that maintenance of adequate circulatory 
Ca2+ levels in patients with disturbances in Ca2+ homeostasis should be a priority in 
order to prevent bone loss at older age.
IntroductIon
Maintenance of adequate Ca2+ levels is of crucial 
importance for many physiological processes in the body 
including neuronal excitability, muscle contraction and 
bone formation. Bone is the major site of Ca2+ storage in 
the body, and formation and mineralization by osteoblasts 
as well as osteoclastic bone resorption, contribute to the 
maintenance of Ca2+ equilibrium in the circulation. Serum 
Ca2+ is tightly regulated through the concerted interactions 
of kidneys, intestines and bone. Transcellular Ca2+ (re)
absorption is an important process in maintaining Ca2+ 
balance by these tissues [1, 2]. 
Previously, we published on the phenotype of mice 
lacking the epithelial Ca2+ channel Trpv5 (Trpv5-/-) [3]. 
TRPV5 is a Ca2+-selective transient receptor potential 
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channel that is expressed in renal epithelial cells and 
crucial for reabsorption of calcium. In Trpv5-/- mice, 
besides hypercalciuria, intestinal Ca2+ hyperabsorption 
takes place by upregulation of the close homolog of 
Trpv5, Trpv6. This process is impaired when 1,25(OH)2D3 
bioactivity is disturbed as shown in double knockout mice 
for TRPV5 and 1α-hydroxylase (synthesizes 1,25(OH)2D3) 
and by treatment of Trpv5-/- mice with a vitamin D receptor 
antagonist, ZK191784 [4, 5]. 
A detailed study on bone in these mice revealed that 
Trpv5 has a direct role in bone [6]. Trpv5-/- mice display 
an aberrant bone phenotype, including reduced cortical 
and trabecular bone thickness. Within bone, TRPV5 
appears to be expressed by osteoclasts exclusively at the 
site where bone resorption takes place. Despite enhanced 
osteoclastogenesis, both in vivo and in vitro, bone 
resorption is seriously disturbed in mice lacking Trpv5, 
indicating that TRPV5 is required for proper osteoclast 
function. 
It is known that increasing age is accompanied 
by changes in Ca2+ homeostasis, including reduced 
Ca2+ absorption from the diet, reduced vitamin D 
availability, which predisposes older persons to disorders 
related to Ca2+ homeostasis, particularly secondary 
hyperparathyroidism and osteoporosis [7, 8]. In addition, 
the capacity of 1,25(OH)2D3 to stimulate intestinal Ca2+ 
absorption declines with age, whereas circulating levels of 
PTH rise with age in rats and humans [9, 10]. Moreover, 
age-related increase in PTH levels may play an important 
role in changes in bone remodeling. Bone loss occurs 
universally with aging, leading to a reduction in bone 
mass and strength eventually leading to bone fragility and 
increased risk of osteoporotic fractures in the elderly [7, 
11].
We previously demonstrated that compared to 
wildtype (Trpv5+/+) mice, both renal Ca2+ reabsorption 
and intestinal Ca2+ absorption were reduced during aging 
in Trpv5-/- mice, of which the latter was associated with 
Trpv6 expression [12]. Moreover, elevated vitamin D 
receptor protein levels observed in the intestine in older 
mice are indicative for vitamin D resistance. 
In this study we aimed to investigate the bone 
phenotype of aging Trpv5+/+ and Trpv5-/- mice by detailed 
analyses of serum and urine parameters related to calcium 
homeostasis and bone resorption, bone microarchitecture, 
mineralization and strength in vivo. Moreover, bone 
marrow cultures from long bones were performed to 
assess osteoblast and osteoclast differentiation in 78-week-
old Trpv5+/+ and Trpv5-/- mice. Finally, the impact of aging 
on calcium homeostasis and bone-related gene expression 
was examined in femurs and bone marrow cultures from 
both genotypes.
results
serum 1,25(oH)2d3 and PtH are age-dependently 
elevated in trpv5-/- mice
No difference in serum Ca2+ levels were observed 
between Trpv5+/+ and Trpv5-/- mice at all three ages (Table 
1). Serum Ca2+ in the oldest age group (78 weeks) was 
measured with a different calcium assay, which hampers 
direct comparison between the younger 2 age cohorts 
with the 78-week-old mice. However, using the same 
assay, previous measurements in an aging cohort of 
wild type mice up to 2 years of age yielded similar Ca2+ 
levels compared to the 78-week-old mice in this study 
(Supplementary Table 2). In Trpv5+/+ mice, 1,25(OH)2D3 
(pmol/l) and PTH (pg/ml) levels increased significantly 
with aging (Figure 1 and Table 1). In Trpv5-/- mice a similar 
age-related increase in serum 1,25(OH)2D3 was observed 
but serum 1,25(OH)2D3 levels were significantly higher in 
Trpv5-/- compared to their Trpv5+/+ littermates at 10 and 
78 weeks of age. PTH level in Trpv5-/- mice increased 
table 1: serum measurements in Trpv5+/+ and Trpv5+/+ mice during aging
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with age but was only significantly higher at 52 weeks 
age compared to Trpv5+/+ mice. In 10-week-old Trpv5-/- 
mice, both PTH and 1,25(OH)2D3 were at a level that is 
not reached before 52 weeks of age in Trpv5+/+ littermates 
(Figure 1 and Table 1). 
trabecular and cortical bone mass are reduced in 
trPV5-/- mice
In Trpv5+/+ mice, trabecular bone thickness (Figure 
2A), trabecular spacing and structure model index (SMI) 
were increased in older mice, whereas trabecular number 
and connectivity density demonstrated an age-related 
decline (Supplementary Table 3). Trpv5-/- mice showed 
similar age-related changes as Trpv5+/+ mice in the 
trabecular compartment although their trabecular bone 
thickness increased less pronounced during aging resulting 
in significantly lower bone mass in 52- and 78-week-old 
mice compared to their Trpv5+/+ littermates (Figure 2A).
Within the subtrochanteric bone compartment, an 
age-related decrease in cortical thickness (Figure 2B) 
was seen in Trpv5+/+ mice, while a stable cortical bone 
volume was maintained throughout life. Consistent 
with these findings, we found the endocortical volume 
(i.e. marrow cavity volume) to be increased with aging 
(Figure 2C-2D). TRPV5 deficiency led to similar age-
related changes, but cortical thickness (Figure 2B) and 
cortical volume (Supplementary Table 3) were reduced 
at all ages compared to the Trpv5+/+ mice. At 78 weeks 
of age, both endocortical volume and cortical porosity 
were significantly greater in the Trpv5-/- mice compared 
to their non-deficient littermates (Figures 2C and 2D, 
respectively). Other cortical parameters, such as moment 
of inertia and perimeter also increased during aging 
but they were not different between the genotypes 
(Supplementary Table 3).
Mineralization of the trabecular structure is 
reduced in trpv5-/- mice
Tibial quantitative backscattered electron (qBEI) 
imaging showed in trabecular bone an age-related increase 
in the average and most abundant mineralization densities 
(CaMean and CaPeak, respectively) and an age-related 
reduction in the areas undergoing primary mineralization 
(CaLow) in wildtype mice (Figures 3A, 3B and 3D). The 
heterogeneity of mineralization (CaWidth) did not alter 
during aging in Trpv5+/+ mice (Figure 3C). Trpv5-/- mice 
demonstrated age-related changes for all qBEI parameters 
measured being positively correlated with age for 
CaMean, CaPeak and CaWidth (Figures 3A, 3B and 3C, 
respectively), whereas CaLow was negatively correlated 
(Figure 3D). Both CaMean and CaPeak were reduced in 
the younger Trpv5-/- mice, being significant at 52 weeks 
Figure 1: Trpv5 deficiency leads to elevated serum 1,25(OH)2d3 and PtH levels. Depicted is an illustration of temporal 
changes in serum levels of hormones involved in calcium homeostasis. Based on the measured serum calcium levels in the 10 and 52-
week old animals and calcium measured of 78-week-old male mice in this and a previous study, we have depicted calcium to be constant 
irrespective of age and genotype (black dotted line, not representing an actual value). Both 1,25(OH)2D3 (triangle symbols) and PTH (round 
symbols) levels are elevated in 10-week-old Trpv5-/- (open symbols) compared to Trpv5+/+ mice (closed symbols). In fact, the serum levels 
for both hormones in 10-week-old TRPV5 deficient mice are similar to those in 52-week-old Trpv5+/+ mice. The data presented are not 
longitudinal and hence should not be presented as a line graph but they serve solely as an illustration for temporal serum changes in mice 
lacking Trpv5. We emphasized this by disconnecting the lines from the actual measurements. 
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and 10 weeks of age versus Trpv5+/+ mice, respectively 
(Figures 3A and 3B, respectively). In the metaphyseal 
cortical bone, all parameters changed with age in both 
genotypes (Supplementary Table 4). In contrast to the 
trabecular data, in cortical bone no difference for any 
of the parameters at any age was observed between the 
Figure 2: Trpv5 deficiency leads to reduced bone thickness. Bone microarchitectural parameters from male Trpv5+/+ (white bars) 
and Trpv5-/- (black bars) mice at 10, 52 and 78 weeks of age were determined by μCT analysis (n = 5-11). A. trabecular thickness in the 
femoral head, b. cortical thickness, c. endocortical volume and d. cortical porosity in the subtrochanteric area. e. scan regions for the 
calculations on trabecular (1) and cortical bone (2). Data are presented as means ± SEM. * p < 0.05 versus Trpv5+/+. $ p < 0.001 vs Trpv5+/+. 
Significant aging effects for a genotype are indicated by horizontal lines.
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genotypes (Supplementary Table 4). Both in Trpv5+/+ 
and Trpv5-/- mice, cortical CaMean, CaPeak and CaWidth 
increased with age, whereas CaLow was negatively 
correlated (Supplementary Table 4). In the cortices of 
both genotypes osteocyte lacunae number and size were 
assessed. No difference was found for both parameters 
when corrected for cortical bone area (Supplementary 
Figure 1).
bone resorption in trpv5+/+ and trpv5-/- bones 
during aging
Bone resorption as assessed by urinary DPD was 
similar between the Trpv5+/+ mice age groups (Figure 4A). 
In contrast, Trpv5-/- mice demonstrated an age-related 
increase in DPD levels. At 10 and 52 weeks of age, Trpv5-
/- mice had significantly lower DPD levels compared to 
Trpv5+/+ mice but at 78 weeks of age, these were similar 
in both genotypes (Figure 4A). Osteoclast numbers and 
surface in femoral bone sections of 78-week-old were 
not significantly different between genotypes (Figures 
4B and 4C, respectively). In bone marrow cultures 
derived from 78-week-old mice, osteoclast numbers 
generated from Trpv5-/- precursor cells were significantly 
lower (Figure 4D), but this caused no difference in in 
vitro bone resorption (Figures 4E). Frequencies of bone 
marrow populations containing osteoclast precursors (i.e. 
immature blasts, myeloid blasts, and monocytes [13] as 
evaluated by flow cytometry were not different between 
Trpv5+/+ and Trpv5-/- mice (Supplementary Table 5). The 
only different cell population in the bone marrow pool was 
Figure 3: Bone mineralization is affected in Trpv5-/- mice. Using quantitative backscattered electron imaging, the tibial BMDD 
was assessed from male Trpv5+/+ (white bars) and Trpv5-/- (black bars) mice at 10, 52 and 78 weeks of age (n = 3-6). Parameters were 
measured in the metaphyseal spongious bone compartment with respect to A. CaPeak, b. CaMean, c. CaWidth (all expressed as units of 
[wt%Ca]) and d. CaLow (expressed as percentage bone area). Values are presented as mean ± SEM. * p < 0.05 versus Trpv5+/+. # p < 0.01 
vs Trpv5+/+.$ p < 0.001 vs Trpv5+/+. Significant aging effects for a genotype are indicated by horizontal lines.
Oncotarget24933www.impactjournals.com/oncotarget
Figure 4: bone resorption is reduced in Trpv5-/- mice until 52 weeks of age. A. Urinary DPD measurement in 10, 52 and 
78-week-old male Trpv5+/+ (white bars) and Trpv5-/- (black bars) mice. b. osteoclast number and c. osteoclast surface per bone surface 
in TRAP-stained femoral bone section of 78-week-old male Trpv5+/+ and Trpv5-/- mice. d. osteoclast number and e. osteoclast surface 
assessed in bone marrow-derived osteoclast cultures from 78-week-old male Trpv5+/+ and Trpv5-/- mice. Values are presented as mean ± 
SEM. * p < 0.05 versus Trpv5+/+. $ p < 0.001 vs Trpv5+/+.
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Figure 5: Aging Trpv5-/- mice demonstrate high Vdr expression. Total femoral RNA was isolated from male Trpv5+/+ (white bars) 
and Trpv5-/- (black bars) mice at 10, 52 and 78 weeks of age (n = 3-12). A. Trpv6, b. Casr, c. Vdr, d. Acp5, e. Ctsk and F. Phex mRNA. 
Gene expression was corrected for the housekeeping gene Hprt and expression in Trpv5+/+ at 10 weeks was set to 1. Normalized for the 
housekeeping gene Values are presented as mean ± SEM. *p < 0.05 versus Trpv5+/+. # p < 0.01 vs Trpv5+/+.$ p < 0.001 vs Trpv5+/+. Significant 
aging effects for a genotype are indicated by horizontal lines.
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the lymphoid precursor cells, which were significantly 
lower in the Trpv5-/- mice at 78 weeks.
Trpv5 deficiency does not affect bone strength
Three-point-bending tests were performed on a 
subset of femurs from male 78-week-old Trpv5+/+ and 
Trpv5-/- mice. There were no differences in maximum 
load, stiffness or energy of the femurs between the 
genotypes (Supplementary Figures 2A-2C). Moreover, 
Young’s modulus, a measure for elasticity of the bone, was 
unaffected (Supplementary Figure 2D). 
old trpv5-/- and trpv5+/+ mice show differences in 
femoral gene expression patterns
Next, we generated femoral bone gene expression 
profiles for both genotypes at 10, 52 and 78 weeks of age 
by focusing at genes involved in calcium transport and 
homeostasis, osteoclast function, bone metabolism and 
phosphate homeostasis. 
calcium transport and homeostasis
Trpv5 mRNA was similarly expressed in femurs of 
10-, 52- and 78-week-old Trpv5+/+ mice (Supplementary 
Table 6). Trpv6 mRNA expression in femurs of Trpv5+/+ 
mice was lower in the 78-week-old animals compared to 
younger age groups, though not significant (Figure 5A). 
Calcium sensing receptor (Casr) and vitamin D receptor 
(Vdr) mRNA expression were negatively and positively 
correlated with age in Trpv5+/+ mice, respectively (Figure 
5B and 5C, respectively). Other genes involved in 
transcellular Ca2+ transport, i.e. calbindin-D9K (S100g), 
sodium/calcium exchanger 1 (Ncx1) and plasma 
membrane calcium ATPase 1 (Atp2b1) did not change 
during aging of Trpv5+/+ mice (Supplementary Table 
6). Comparing Trpv5-/- and Trpv5+/+ mice, no significant 
differences were observed for any of the genes related to 
calcium homeostasis at any time point. Besides reduced 
Vdr expression at 52 and 78 weeks of age (Figure 5C) 
and increased Ncx1 expression at 78 weeks of age 
(Supplementary Table 6).
osteoclast function
The mRNA expression of the osteoclast marker 
genes for tartrate-resistant acid phosphatase (Acp5), 
cathepsin K (Ctsk) and the calcitonin receptor (Ctr) was 
negatively correlated with age in both genotypes (Figures 
5D-5E and Supplementary Table 6). All osteoclast marker 
genes assessed were slightly but consistently elevated in 
the Trpv5-/- compared to Trpv5+/+ mice (Figures 5D-5E and 
Supplementary Table 6), but only reached significance for 
Acp5 and Ctsk. 
bone metabolism and phosphate homeostasis
 We also assessed several genes associated with 
bone metabolism and phosphate homeostasis. Among 
them, phosphate regulating endopeptidase homolog, 
X-linked (Phex), osteopontin (Spp1) and sclerostin (Sost)) 
showed reduced mRNA expression with aging in Trpv5+/+ 
mice (Figure 5F and Supplementary Table 6). Ankylosis, 
progressive homolog (Ank), Fibroblast growth factor 23 
(Fgf23) and Klotho (Kl) were not modulated in an age-
related manner in these mice (Supplementary Table 6). 
As for the Trpv5+/+ mice, Phex, Spp1 and Sost expression 
showed a negative correlation with age in Trpv5-/- mice 
(Figure 5F and Supplementary Table 5). Only Phex 
expression at 78 weeks of age was significantly different 
in Trpv5-/- mice compared to Trpv5+/+ mice (Figure 5F). 
Overall, the Trpv5-/- mice showed similar age-
related trends as did the Trpv5+/+ mice but for some genes 
significantly higher expression of bone-related genes was 
observed at 78 weeks of age compared to the Trpv5+/+ 
mice. In bone marrow-derived osteoblasts and osteoclasts, 
all marker genes studied were expressed at lower levels 
in the Trpv5-/- mice, but none of these differences reached 
significance (Supplementary Table 7). 
dIscussIon
Trpv5 deficiency strongly stresses the Ca2+ 
homeostasis in order to maintain stable plasma Ca2+ levels 
[3, 6]. Here, we demonstrate that mice lacking Trpv5 are 
able to maintain similar serum Ca2+ levels as their Trpv5-
expressing counterparts during aging up to at least 78 
weeks of age. This is achieved by pronounced age-related 
increments in serum 1,25(OH)2D3 and PTH. Age-related 
increases of these hormones were also observed in Trpv5-
/- mice but interestingly at 10 weeks of age 1,25(OH)2D3 
levels were already at the level of older (52 weeks) 
Trpv5+/+ mice, pointing to premature aging in this respect 
in Trpv5-/- mice. The stress on the Ca2+ homeostasis is 
paralleled by a reduced degree of bone mineralization 
and accelerated changes in bone microarchitecture as 
exemplified by reduced bone thickness. 
normocalcemia in trpv5-/- mice is associated with 
elevated serum 1,25(oH)2d3 and PtH
Trpv5-/- mice predominantly suffer from renal 
calcium loss, which is initially compensated by increased 
intestinal calcium hyperabsorption through TRPV6 
followed by reduced bone mass and mineralization, to 
retain normocalcemia [3]. This compensatory mechanism 
is accompanied by elevated levels of 1,25(OH)2D3 
and PTH already at 10 weeks of age. Later in life, 
1,25(OH)2D3 levels further increase in Trpv5-/- mice even 
to levels exceeding 1300 pmol/l. These extremely high 
1,25(OH)2D3 levels may explain that at 78 weeks of age 
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the PTH levels in the Trpv5-/- are lower compared to the 
Trpv5+/+ mice. The continuous exposure of an organism 
to elevated PTH and 1,25(OH)2D3 levels has adverse 
consequences for the skeleton. Circulating levels of PTH 
rise with age in rats and humans [9, 10]. From human 
clinical studies, it has become apparent that prolonged 
exposure to high PTH (p.e. primary hyperparathyroidism) 
indirectly increases osteoclast activity and decreases 
age-related osteoblast replicative activity [14-17], both 
contributing to bone loss.
Elevated PTH levels during human aging are at least 
partially caused by a decline in vitamin D levels, which 
is associated with reduced calcium absorption. Vitamin D 
levels are associated with elevated bone mineral density 
and reduced risk of fracture [18]. In contrast to the anabolic 
vitamin D effects on the skeleton in humans, Lieben et al. 
showed that exposure to high 1,25(OH)2D3 levels leads 
to reduced bone mineralization in mice [19]. In addition, 
Smith and coworkers showed that chronic high vitamin 
D levels in mice lead to a decrease in cortical thickness 
and a decline in bone stiffness [20]. In the current study, 
we demonstrate upregulation of the Vdr gene at the level 
of the femoral bone and strongly elevated 1,25(OH)2D3 
levels in the oldest Trpv5-/- age group. Although we have 
no data to support this, upregulation of Vdr expression and 
high serum 1,25(OH)2D3 levels would facilitate enhanced 
vitamin D signaling within bone. Enhanced vitamin D 
signaling may thus be a mechanism to limit the influx of 
Ca2+ into bone, which would contribute to retaining serum 
Ca2+ but at the expense of bone mineralization.
Another mechanism that may contribute to retaining 
normocalcemia is osteocytic osteolysis. Through this 
process, osteocytes are capable of resorbing the lacunae 
around them, resulting in the liberation of ions in case of 
a strong Ca2+ demand, such as lactation [21-23]. Suffering 
from a chronic negative Ca2+ balance but keeping serum 
levels constant, osteocytic osteolysis in Trpv5-/- mice may 
suffice to restore serum Ca2+, which in turn would cause 
the observed increased cortical porosity. Although minute 
changes in osteocyte function may have great impact due 
to their numbers within bone, we failed to show detectable 
changes in osteocytic lacunar size or number at 78 weeks 
of age.
Mineralization of bone is affected in Trpv5-/- mice
In concordance with a chronic Ca2+ insufficiency 
in Trpv5-/- mice are our findings on bone mineralization 
density. Although no effects were seen at the level of the 
tibial cortex, mineralization density was decreased in 
the trabecular bone along with non-significantly larger 
areas of low mineralized bone observed in the 52- and 
78-week-old Trpv5-/- mice compared to Trpv5+/+ mice. 
As we have shown previously, the enhanced intestinal 
Ca2+ uptake could not fully compensate for the renal Ca2+ 
loss in young Trpv5-/- mice, leading to reduced skeletal 
mineralization [6]. Later in life, the persisting stress on 
Ca2+ homeostasis may have led to the observed increased 
undermineralization in old Trpv5-/- mice but also to the 
increased endocortical osteoclast and osteocyte activity.
Trpv5 deficiency accelerates bone loss
Aging is associated with bone loss by thinning of 
cortical bone and loss of the trabecular network [24]. 
Indeed, we found a decrease in cortical thickness with 
aging and a reduction of the trabecular bone volume 
fraction and connectivity, despite increased thickness of 
the remaining trabecular bone. Previous studies looking at 
bone microarchitecture in aging mice found similar results 
[25-27]. Glatt et al observed an age-related decline in the 
trabecular bone volume fraction (BV/TV) [25], something 
we saw until the age of 52 weeks but not thereafter, despite 
a significant age trend. In line with our data, Ferguson et 
al. described cortical expansion by periosteal apposition 
in male mice to compensate for trabecular bone loss and 
reduced mineralization [26]. Hamrick and coworkers 
showed BMD loss, periosteal expansion and endosteal 
resorption up to 29 months of age [27]. Interestingly, a 
concurrent increase in endosteal apposition was observed 
at this age, for which no explanation was provided but 
it may be to counteract excessive endosteal bone loss. 
Nevertheless, it may provide an anabolic time-window 
for interventions to improve bone quantity/quality later 
in life. We did not observe differences in bone resorption 
between 10 and 78 weeks of life as measured by urinary 
DPD, which corresponds with the study by Hamrick, who 
showed increased bone resorption only after 18 months 
of age [27]. 
Trpv5 deficiency led to a more accelerated bone 
aging phenotype, including reduced trabecular and cortical 
bone mass as well as increased endocortical bone volume 
later in life compared to Trpv5+/+ mice. For example, the 
Trpv5-/- mice have a cortical thickness at 10 weeks of age 
that is not reached until Trpv5+/+ at 78 weeks of age.
osteoclast number and bone resorption seems 
unaffected in 78-week-old Trpv5-/- mice
In contrast to our study in young mice where we 
found increased numbers of osteoclasts in 10-week-old 
Trpv5-/- mice[6], we observed no differences in osteoclast 
number between Trpv5+/+ and Trpv5-/- mice, but both 
genotypes showed lower osteoclast formation at 78 
weeks compared to 52 weeks. To explain the discrepancy 
between the previous and current study, we assessed 
whether exhaustion of osteoclast precursors could have 
taken place in the bone marrow. However, apart from a 
reduction in the number of lymphoid precursor cells, we 
did not find a reduction in monocyte number. 
Despite having a bone resorption defect in early 
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life [6] and reduced urinary DPD levels in Trpv5-/- mice 
at 52 weeks, the current study showed that endocortical 
bone resorption in Trpv5-/- mice exceeds that of Trpv5+/+ 
mice between 52 and 78 weeks of age, resulting in an 
enlargement of the marrow space (endocortical volume) 
at the level of the subtrochanter. In line with this would be 
the elevated expression levels of a few osteoclast markers 
in femurs of 78-week-old Trpv5-/- mice. However, bone 
resorption was not different between the genotypes at 
this age, in vivo and ex vivo, as shown by DPD levels, 
histomorphometry and bone marrow-derived osteoclast 
cultures. Apparently, old Trpv5-/- mice seem to be able 
to regain their bone resorption capacity, independent of 
TRPV5. Perhaps, prolonged high levels of circulating 
1,25(OH)2D3, PTH or another yet unknown mechanism 
following TRPV5 deficiency has a restorative effect at the 
level of osteoclast activity on the skeleton of these mice. 
This suggests that the reduced bone resorption caused by 
TRPV5 deficiency that we reported previously for mice at 
10 weeks of age [6] and is apparent by the decreased DPD 
levels at 52 weeks, may not have been entirely intrinsic 
and is overcome at older age.
bone strength is not compromised in old trpv5 
-/- mice
The combination of reduced bone mass and 
increased endosteal resorption suggests that life-long 
stress on calcium homeostasis due to TRPV5 deficiency 
weakens the skeleton of old mice. Besides the effects 
on cortical bone mass, we observed increased cortical 
porosity during aging but especially in the 78-week-
old mice lacking TRPV5. Cortical porosity has been 
appreciated as an age-related phenomenon in the elderly 
and an important determinant of bone strength but the 
precise mechanism behind this process remains unclear 
[28]. Besides these effects on the skeleton of Trpv5-/- mice, 
the 3-point-bending tests yielded similar outcomes for 
both genotypes at 78 weeks of age. The reason for this 
remains obscure, but may be due to a combination of 1) 
changes in the composition or the organization of the 
extracellular matrix leading to structural changes within 
the skeleton that could not be assessed through 3-point 
bending; 2) reduced mineralization in Trpv5-/- mice that 
renders bone to be more flexible; 3) non-significantly 
increased cortical perimeter in Trpv5-/- mice between 52 
and 78 weeks of age (1.5 mm3) compared to Trpv5+/+ mice 
(1.2 mm3) that may aid to counteract loss of bone strength. 
Finally, mice may possess a yet unknown ‘compensation’ 
mechanism that in case of bone loss protects them from a 
fracture, something that is rarely seen in mice.
Human ca2+ homeostasis and bone metabolism
Several disease states, such as chronic kidney 
diseases and intestinal malabsorption syndromes (e.g. 
celiac disease, intestinal surgery, aging and vitamin D 
deficient nutrition) in humans cause continuous stress on 
the maintenance of adequate serum Ca2+ levels, and a clear 
relationship has been established with bone deterioration 
[29-32]. The phenotype of the Trpv5-/- mice suggests that 
maintenance of adequate circulatory Ca2+ in these patients 
should be a priority in order to prevent bone loss and 
increased risk fractures at older age.
In conclusion, this study demonstrates that TRPV5 
is important for normal bone development and that an 
unfavorable Ca2+ balance persisting during aging leads 
to accelerated bone loss in Trpv5-deficient mice. The 
strongly elevated vitamin D levels in Trpv5-/- mice may aid 
in restoring serum Ca2+ but at the expense of maintaining 
bone mass and/or mineralization in vivo. The TRPV5 
deficient mouse appears to be a suitable model for lifelong 
challenge of calcium homeostasis and its consequences for 
bone metabolism.
MAterIAls And MetHods
Animals
Male homozygous TRPV5 null (Trpv5-/-) and 
Trpv5+/+ mice were generated as described before [3]. and 
were fed standard chow and given water ad libitum. At the 
age of 10, 52 and 78 weeks, mice were sacrificed (group 
sizes varied between 4-12) and serum, urine and bones 
were collected. The animal ethics board of the Radboud 
University Nijmegen approved all animal experimental 
procedures.
Analytical procedures
Serum Ca2+ was calorimetrically determined with 
a Ca2+ assay kit (Sigma) according to the manufacturer’s 
description at 595 nm, using a Bio-Rad microplate 
reader (Bio-Rad) or using a home-made calcium assay as 
described before [33]. Serum PTH levels were measured 
using a mouse intact PTH ELISA kit following standard 
procedure (Immutopics, San Clemente, CA, USA). 
Serum 1,25(OH)2D3 concentrations were measured by 
immunoextraction followed by quantitation by 125I-RIA 
(IDS, Boldon, UK) [6]. Urinary total deoxypyridinoline 
(DPD) cross-links were determined, using the Metra DPD 
assay according to the guidelines (Quidel). 
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Microcomputed tomography (μCT)
Femurs were scanned using the SkyScan 1072 
microtomograph (Bruker MicroCT) with a resolution of 
7 µm and subsequently analyzed as described in detail 
before [6]. According to guidelines recently published 
[34] the following settings were used: X-Ray power and 
tube current were 40 kV and 0.25 mA, respectively. Beam 
hardening (20%) was reduced using a 1 mm aluminum 
filter, ring-artefacts were reduced (set at 5), exposure 
time was 5.9 seconds and an average of three pictures 
was taken at each angle (0.9º) to generate final images. 
Using different software packages from Bruker MicroCT 
(NRecon, CtAn and Dataviewer), bone microarchitectural 
parameters were assessed in trabecular and cortical bone 
of all mice (n = 14 for both genotypes). The trabecular 
bone parameters trabecular tissue volume, bone volume, 
trabecular volume fraction (BV/TV), trabecular thickness, 
trabecular number, connectivity density and structure 
model index were determined in the femoral head (scan 
area 0 - 3.25 mm of proximal femur). In the subtrochanter 
area (scan area 3.25 - 6.3 mm from femoral head), cortical 
volume, cortical thickness, cortical porosity, polar moment 
of inertia (MOI; proxy for bone strength) and perimeter 
were analyzed. For image processing, trabecular bone was 
manually selected and cortical bone was automatically 
selected. We used global thresholding for segmentation, 
followed by applying optimized threshold levels for 
trabecular and cortical bone measurements. 
bone mechanical properties (3-point bending)
Femurs were stored in phosphate-buffered saline at 
-20°C until further use. Before the 3-point bending test, 
femurs were scanned according to the settings mentioned 
above. The procedure was carried out as previously 
described in detail [35]. Briefly, femurs were placed in 
a custom made 3-point bending device, with the lower 
loading posts 10 mm apart. Mechanical testing was 
performed, using a Single Column Lloyd LRX System 
(Lloyd Instruments). Displacement (mm) and force (N) 
were registered. Using the same settings for filtration, 
segmentation and binarization as mentioned above in the 
μCT section, the MOI, reflecting the ability of the bone 
to withstand torsion, was calculated using Ct Analyzer 
software (Bruker MicroCT). This was determined in the 
μCT scan-derived cross-section that corresponded to 
the fracture site resulting from the bending test. From 
the resulting displacement to force graphs as well as the 
MOI values, ultimate force (N), stiffness (N/mm), energy 
(Nmm) and elastic modulus (MPa) were determined as 
described before [36].
Quantitative backscattered electron imaging
Dissected tibiae were routinely fixed and dehydrated 
in ethanol, and embedded in polymethylmethacrylate. 
Sample blocks were trimmed using a low speed diamond 
saw (Isomet-R, Buehler Ltd.). Sectioned bone surfaces 
were sequentially ground with sand paper with increasing 
grid number followed by polishing with diamond grains 
(size down to 1 micron) on hard polishing clothes by a 
precision polishing device (PM5 Logitech, Glasgow, 
Scotland). Finally the sample surface was carbon coated 
by vacuum evaporation (Agar SEM Carbon Coater) for 
scanning electron microscopy.
Bone mineralization density distribution (BMDD) 
was determined in the metaphyseal spongiosa and in the 
midshaft cortical bone by qBEI using a digital scanning 
electron microscope (DSM 962, Zeiss) equipped with 
a four-quadrant semiconductor backscattered electron 
detector as extensively described before [37, 38]. The 
accelerating voltage of the electron beam was set to 20 
kV, the probe current to 110 pA, and the working distance 
to 15 mm. The cancellous and cortical bone areas were 
imaged at 200x nominal magnification (corresponding 
to a pixel resolution of 1 µm/pixel. From these digital 
images, grey level histograms were deduced, displaying 
the percentage of bone area occupied by pixels of a 
certain gray level. The transformation of these into 
calcium weight percent (wt%Ca) histograms led to a bin 
width of 0.17 wt%Ca. A technical precision of 0.3% was 
achieved. The BMDD parameters like the mean (weighted 
mean) CaMean and most frequently occurring calcium 
concentration CaPeak (peak position of the BMDD) in the 
sample, the width of the distribution CaWidth (full width 
at half maximum; ∆wt%Ca) reflecting the heterogeneity in 
matrix mineralization and CaLow, the percentage of bone 
below 17.68 wt%Ca (primary mineralization)[39].
osteocyte density measurements
qBEI Images of cortical bone (nominal 
magnification 200X) with 1 μm pixel resolution were 
used to determine osteocyte lacunae number. The mean 
size was evaluated from the 2D images of the lacunae 
as well as the percentage of the sectioned bone surface 
occupied by these lacunae (density). This was done, using 
the software package Bioquant (Version 7.20; Bioquant 
image analysis corporation).
bone histomorphometry
After excision, femurs were routinely embedded in 
methylmetacrylate as described before [6]. Six µm sections 
were subjected to tartrate-resistant acid phosphatase 
(TRAP) staining. Sections were deacrylated, hydrated and 
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rinsed in 0.2 M sodium acetate / 50 mM tartaric acid for 5 
minutes. Naphtol AS-MX (0.5 mg/ml) and 1.1 mg/ml Fast 
red TR salt (both from Sigma) were added and incubated 
for 120 minutes at 37°C. Counterstaining was performed 
with haematoxylin for 5 seconds and after air-drying, the 
sections were embedded in Permount (Thermo Fischer 
Scientific). Images were taken with a Nikon Eclipse E400 
system (Nikon, Lijnden, the Netherlands) and osteoclast 
number (Oc.N) and surface (Oc.S) were determined per 
total bone surface (BS), using Bioquant software. 
bone marrow cultures
Bone marrow cells derived from 78-week-old 
mice stimulated towards osteoclasts and osteoblasts were 
cultured as described in detail [6, 40]. After 6 days of 
osteoclast culture, TRAP and coomassie brilliant blue 
stainings were used to stain for osteoclasts and resorption 
pits on bone slices left behind by osteoclasts, respectively 
[6]. Osteoclast number and resorption surface were 
determined and resorption surface per osteoclast was 
calculated, using the freely available ImageJ software 
(version 1.41; http://rsbweb.nih.gov/ij/). Osteoblast at 
day 14 were washed with PBS and taken up in TriZol for 
isolation of total RNA as described below.
Flowcytometric analysis
Frequencies of bone marrow populations containing 
osteoclast precursors were determined by flowcytometry, 
essentially as described in de Vries et al. [13]. Bone 
marrow cells from approximately 10- and 22-month-
old mice were collected, washed and counted. All 
immunofluorescent labelings and washes took place in 
FACS buffer (PBS containing 1% BSA). Bone marrow 
cell suspensions were spun down at 1500 rpm for 5 min 
at 4ºC) and incubated for 30 min in 25 μl per 106 cells 
biotinylated ER-MP12, recognizing CD31 [41]. Cells were 
washed once and incubated in 25 μl per 106 cells FACS-
buffer containing FITC-conjugated ER-MP20, recognizing 
Ly6C [41], and streptavidine-phycoerythrin (PE; Becton 
Dickinson; 10 μl per 106cells) for 30 min. Finally, cells 
were fixed in 1% vol/vol paraformaldehyde in PBS for 15 
min, washed and taken up in PBS. Cells were analyzed 
using a BD FACS Calibur and data were processed using 
Diva software (Becton Dickinson).
rnA isolation, cdnA synthesis and real-time Pcr
Pulverized material from mouse femurs (including 
bone marrow) was resuspended in Trizol Reagent 
(Gibco). RNA isolation, cDNA synthesis and real-time 
PCR on these femur samples as well as on the samples 
from the bone marrow cultures were performed as 
described previously [42]. Primer and probe sequences 
and concentrations used for real-time PCR are listed in 
Supplementary Table 1. The gene hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) was used as an internal 
control to normalize for differences in RNA extraction 
and degradation as well as for efficiency of the cDNA 
synthesis. Data were presented as relative mRNA levels 
calculated by the equation 2-∆Ct (∆Ct (cycle threshold) = Ct 
of gene of interest minus Ct of housekeeping gene).
statistics
In all experiments values are expressed as mean 
± SEM unless stated otherwise. Differences between 
genotypes were tested for significance by AN(C)OVA and 
adjusted for age. In the in vivo studies, regression analyses 
were performed to assess age-related changes. Two-way 
ANOVA was performed to assess for interaction between 
age and genotype. Values were considered significantly 
different at p < 0.05.
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